RNS Number : 9534Z Renalytix PLC 20 September 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Announces Change to Board of Directors LONDON and SALT LAKE CITY , 20 September 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman , non-executive director
RNS Number : 0215Z Renalytix PLC 12 September 2022 Renalytix plc ("Renalytix" or the "Company") Issue of shares NEW YORK and SALT LAKE CITY , 12 September, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"),
RNS Number : 6200Y Renalytix PLC 08 September 2022 Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference NEW YORK, NY and SALT LAKE CITY, UT ̶ September 8, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a
RNS Number : 3072W Renalytix PLC 17 August 2022 This contains inside information Renalytix plc ("Renalytix" or the "Company") Business update NEW YORK, NY and SALT LAKE CITY, UT August 17, 2022 (GLOBE NEWSWIRE) - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business
RNS Number : 1019V Renalytix PLC 08 August 2022 Renalytix plc ("Renalytix" or the "Company") Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX TM with Primary Care Physicians 98% of 401 Primary Care Physicians confirmed
RNS Number : 7475Q Renalytix PLC 30 June 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY , June 30, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
RNS Number : 8594P Renalytix PLC 23 June 2022 Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 NEW YORK and SALT LAKE CITY , June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022
RNS Number : 4139O Renalytix PLC 10 June 2022 Renalytix plc ("Renalytix" or the "Company") 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Late-breaking data presented at American
RNS Number : 0740O Renalytix PLC 08 June 2022 Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth
RNS Number : 6872N Renalytix PLC 06 June 2022 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort Data shared in oral presentation at American